PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-29.30%
Both yoy net incomes decline, with AVGO at -27.44%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-2.94%
Negative yoy D&A while AVGO is 2.50%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
121.68%
Deferred tax of 121.68% while AVGO is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
21.28%
SBC growth of 21.28% while AVGO is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
-268.71%
Both reduce yoy usage, with AVGO at -2320.00%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-118.57%
AR is negative yoy while AVGO is 16.67%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
-73.63%
Both reduce yoy inventory, with AVGO at -250.00%. Martin Whitman would find a widespread caution or cyclical demand drop in the niche.
No Data
No Data available this quarter, please select a different quarter.
-239.39%
Both reduce yoy usage, with AVGO at -1450.00%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
100.00%
Lower 'other non-cash' growth vs. AVGO's 1200.00%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-58.05%
Both yoy CFO lines are negative, with AVGO at -69.12%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
35.55%
Some CapEx rise while AVGO is negative at -6.67%. John Neff would see competitor possibly building capacity while we hold back expansions.
100.00%
Acquisition growth of 100.00% while AVGO is zero at 0.00%. Bruce Berkowitz sees a mild outflow that must deliver synergy to justify the difference.
-24.54%
Negative yoy purchasing while AVGO stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
153.36%
Liquidation growth of 153.36% while AVGO is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
-100.00%
We reduce yoy other investing while AVGO is 0.00%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
111.50%
We have mild expansions while AVGO is negative at -36.67%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
21.95%
Lower share issuance yoy vs. AVGO's 266.67%, implying less dilution. David Dodd would confirm the firm still has enough capital for expansions.
-28.50%
We cut yoy buybacks while AVGO is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.